WHO recommends Merck COVID pill for non-severe patients


Photo: AFP
Photo: AFP  

PARIS: The World Health Organization (WHO) Wednesday recommended molnupiravir pill for COVID-19 patients having mild symptoms but are at high risk of hospitalisation, such as older people or the unvaccinated. 

The pill, developed by US pharmaceutical Merck, is taken as soon as possible after COVID-19 symptoms develop and then for the following five days.

A WHO group of experts said in the British Medical Journal that people with weak immune systems or chronic disease were also recommended to take the pill if they had non-severe COVID.

However “young and healthy patients, including children, and pregnant and breastfeeding women should not be given the drug due to potential harms,” they said.

The UN agency’s new recommendation was based on the results of six randomised controlled trials involving 4,796 patients, the “largest dataset on this drug so far”.

The trials suggested that molnupiravir reduced the risk of going to hospital, with 43 fewer admissions per 1,000 high-risk patients, as well as speeding up the pace at which symptoms cleared up by an average of 3.4 days.

There was less indication it had an affect on mortality, with just six fewer deaths per 1,000 patients.

The WHO acknowledged “that cost and availability issues associated with molnupiravir may make access to low- and middle-income countries challenging and exacerbate health inequity”.

While vaccines remain the foremost tools in the fight against the pandemic, experts have welcomed the addition of the new oral treatments, which inhibit the virus’ ability to replicate and should withstand variants.

The only other main anti-COVID pill available is Pfizer’s Paxlovid.

However more potential concerns have been raised about Merck’s pill, which the US Food and Drug Administration has not authorised for under-18s because it could affect bone and cartilage growth.



Source link

(Visited 1 times, 1 visits today)
Share this...
Share on Facebook
Facebook
0Tweet about this on Twitter
Twitter
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments